LCG
KPTI icon

Lisanti Capital Growth’s Karyopharm Therapeutics KPTI Stock Holding History

Lisanti Capital Growth’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,371
Closed -$1.24M – 129
2020
Q2 		$1.24M Sell
4,371
-4,568
-51% -$1.35M 0.25% 103
2020
Q1 		$2.58M Buy
8,939
+489
+6% +$135K 0.85% 50
2019
Q4 		$2.43M Buy
+8,450
New +$1.83M 0.64% 62

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lisanti Capital Growth's KPTI Position: Q3 2020 in Review

Lisanti Capital Growth sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 4,371 shares — an estimated $1.24M sold.

Lisanti Capital Growth first reported a position in KPTI in Q4 2019 and held it in 3 quarters. The position peaked at $2.58M in Q1 2020. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

  • Lisanti Capital Growth reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Lisanti Capital Growth sold 4,371 Karyopharm Therapeutics shares in Q3 2020, an estimated $1.24M.
  • Lisanti Capital Growth first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 3 quarters.
  • Lisanti Capital Growth's Karyopharm Therapeutics position peaked at $2.58M in Q1 2020.
  • 157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on Lisanti Capital Growth's 13F filing for Q3 2020, filed 5 Nov 2020.